Status:
COMPLETED
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
Lead Sponsor:
UCB Pharma
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE2
Brief Summary
The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme. Subjects will undergo a 2 - 28 days screening period in which e...
Detailed Description
The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952)in a single dose application scheme. Subjects will undergo a 2-28 days screening period in which eligi...
Eligibility Criteria
Inclusion
- Male and female subjects with idiopathic Parkinson's disease for at least 3 years in duration
- At least 30 years of age
Exclusion
- Patients with atypical Parkinson's or clinically relevant concomitant diseases or medical conditions
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00296192
Start Date
February 1 2006
End Date
June 1 2006
Last Update
October 2 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.